Business News • PR NewsWire • Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension

Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension

Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension

EAST HANOVER, N.J., Sept. 25, 2011 /PRNewswire/ -- Novartis announced new data today from the pivotal Phase III IMPRES clinical trial showing that the investigational therapy QTI571 (imatinib) significantly improved exercise capacity in patients with pulmonary arterial hypertension (PAH)...

View More : http://www.prnewswire.com/news-releases/novartis-study-shows-qti571-significantly-improved-walking-distance-in-patients-...

Releted News by prnewswire

Récord mundial: La linterna más grande del mundo es alemana

Rentrak Announces Official Box Office Numbers for Weekend of September 23, 2011

Brigade Group's Brigade Meadows Kanakapura Road Bangalore, 1.5 BHK, 2 BHK, 3 BHK Apartments Kanakapura Road Bangalore

Novartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension

Hawaiian Airlines Launches Great Hawaiian Winter Getaway Sale

Delcath Announces Further Results From Neuroendocrine Tumor Cohort Presented at European Multidisciplinary Cancer Congress

Hospice Compassus Launches Keeping the Promise 2012: A National Quality Initiative for U.S. Hospice Care